State Street’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,715,554
| Closed | -$140M | – | 4978 |
|
|
2022
Q3 | $140M | Sell |
2,715,554
-1,330,410
| -33% | -$55M | 0.01% | 903 |
|
|
2022
Q2 | $100M | Buy |
4,045,964
+404,301
| +11% | +$8.91M | 0.01% | 1147 |
|
|
2022
Q1 | $91.3M | Buy |
3,641,663
+975,456
| +37% | +$27.4M | ﹤0.01% | 1355 |
|
|
2021
Q4 | $97.1M | Sell |
2,666,207
-1,908,055
| -42% | -$67M | ﹤0.01% | 1322 |
|
|
2021
Q3 | $78.2M | Sell |
4,574,262
-149,364
| -3% | -$2.33M | ﹤0.01% | 1463 |
|
|
2021
Q2 | $63.2M | Buy |
4,723,626
+2,917,258
| +161% | +$71.9M | ﹤0.01% | 1673 |
|
|
2021
Q1 | $92.6M | Sell |
1,806,368
-206,396
| -10% | -$12.4M | 0.01% | 1292 |
|
|
2020
Q4 | $125M | Buy |
2,012,764
+43,529
| +2% | +$2.49M | 0.01% | 983 |
|
|
2020
Q3 | $108M | Buy |
1,969,235
+249,604
| +15% | +$13.4M | 0.01% | 926 |
|
|
2020
Q2 | $98.9M | Buy |
1,719,631
+643,435
| +60% | +$35M | 0.01% | 970 |
|
|
2020
Q1 | $43.2M | Buy |
1,076,196
+25,577
| +2% | +$1.09M | ﹤0.01% | 1355 |
|
|
2019
Q4 | $41.6M | Buy |
1,050,619
+295,171
| +39% | +$5.18M | ﹤0.01% | 1640 |
|
|
2019
Q3 | $5.12M | Sell |
755,448
-1,044,116
| -58% | -$7.84M | ﹤0.01% | 2780 |
|
|
2019
Q2 | $16.7M | Buy |
1,799,564
+1,342,018
| +293% | +$15.5M | ﹤0.01% | 2225 |
|
|
2019
Q1 | $6.36M | Sell |
457,546
-29,809
| -6% | -$341K | ﹤0.01% | 2647 |
|
|
2018
Q4 | $5.32M | Sell |
487,355
-7,629
| -2% | -$80.4K | ﹤0.01% | 2682 |
|
|
2018
Q3 | $6.25M | Buy |
494,984
+50,434
| +11% | +$608K | ﹤0.01% | 2754 |
|
|
2018
Q2 | $5.86M | Buy |
444,550
+19,718
| +5% | +$236K | ﹤0.01% | 2791 |
|
|
2018
Q1 | $5.78M | Sell |
424,832
-18,468
| -4% | -$191K | ﹤0.01% | 2725 |
|
|
2017
Q4 | $2.64M | Buy |
443,300
+15,296
| +4% | +$105K | ﹤0.01% | 3076 |
|
|
2017
Q3 | $3.18M | Sell |
428,004
-1,084
| -0.3% | -$9.01K | ﹤0.01% | 3005 |
|
|
2017
Q2 | $4.02M | Buy |
429,088
+27,896
| +7% | +$205K | ﹤0.01% | 2847 |
|
|
2017
Q1 | $2.92M | Sell |
401,192
-1,600
| -0.4% | -$11.5K | ﹤0.01% | 2949 |
|
|
2016
Q4 | $2.98M | Sell |
402,792
-15,327
| -4% | -$110K | ﹤0.01% | 2941 |
|
|
2016
Q3 | $2.53M | Buy |
418,119
+10,941
| +3% | +$51.7K | ﹤0.01% | 2881 |
|
|
2016
Q2 | $1.83M | Sell |
407,178
-7,563
| -2% | -$28.4K | ﹤0.01% | 3069 |
|
|
2016
Q1 | $1.03M | Buy |
414,741
+2,014
| +0.5% | +$7.33K | ﹤0.01% | 3206 |
|
|
2015
Q4 | $3.34M | Buy |
412,727
+900
| +0.2% | +$6.37K | ﹤0.01% | 2760 |
|
|
2015
Q3 | $2.49M | Sell |
411,827
-7,434
| -2% | -$53.8K | ﹤0.01% | 2904 |
|
|
2015
Q2 | $3.45M | Buy |
419,261
+42,295
| +11% | +$336K | ﹤0.01% | 2831 |
|
|
2015
Q1 | $2.84M | Buy |
376,966
+1,344
| +0.4% | +$10.5K | ﹤0.01% | 2878 |
|
|
2014
Q4 | $2.56M | Buy |
375,622
+24,837
| +7% | +$131K | ﹤0.01% | 2931 |
|
|
2014
Q3 | $1.58M | Sell |
350,785
-328
| -0.1% | -$1.73K | ﹤0.01% | 3114 |
|
|
2014
Q2 | $2.05M | Sell |
351,113
-2,654
| -0.8% | -$14.9K | ﹤0.01% | 3055 |
|
|
2014
Q1 | $2.35M | Buy |
353,767
+22,606
| +7% | +$157K | ﹤0.01% | 2985 |
|
|
2013
Q4 | $1.91M | Sell |
331,161
-117
| -0% | -$603 | ﹤0.01% | 3088 |
|
|
2013
Q3 | $1.84M | Buy |
331,278
+17,445
| +6% | +$189K | ﹤0.01% | 3079 |
|
|
2013
Q2 | $4.44M | Buy |
+313,833
| New | +$4.07M | ﹤0.01% | 2528 |
|
Other funds holding CCXI
State Street's CCXI Position: Q4 2022 in Review
State Street sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 2,715,554 shares — an estimated $140M sold.
State Street first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $140M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- State Street reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- State Street sold 2,715,554 ChemoCentryx, Inc. shares in Q4 2022, an estimated $140M.
- State Street first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- State Street's ChemoCentryx, Inc. position peaked at $140M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.